Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL142029 | 0.81 | — | — | |
| SCHEMBL19785475 | 0.81 | TSHR (0.37) | CA1CA2CA12MMP1MMP2 | |
| SCHEMBL18626021 | 0.79 | CA12 (0.31) | CA1CA2CA12MMP1MMP2 | |
| Hydrochloric Acid SCHEMBL28967104 | 0.79 | CA12 (0.42) | CA1CA2CA12MMP1MMP2 | |
| SCHEMBL18909885 | 0.77 | CA12 (0.40) | CA1CA2CA12MMP1MMP2 | |
| SCHEMBL18909884 | 0.77 | CA12 (0.40) | CA1CA2CA12MMP1MMP2 | |
| SCHEMBL12724859 | 0.77 | CA12 (0.40) | CA1CA2CA12MMP1MMP2 | |
| SCHEMBL23559895 | 0.75 | CA1 (0.31) | CA1CA2ALDH1A1CA7CA14 | |
| SCHEMBL12545610 | 0.74 | CA12 (0.39) | CA1CA2CA12MMP1MMP2 | |
| SCHEMBL19000042 | 0.74 | CA12 (0.39) | CA1CA2CA12MMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240269094-A1 | Treatment of canine dermatitis and skin irritation | WEI EDWARD TAK (US) | 2024-08-15 | — | — | US | disclosed |
| US-20230270883-A1 | ACTIVE AGENT RELEASE PARTICLE | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| WO-2021133770-A1 | NANOPARTICLE WITH SINGLE SITE FOR TEMPLATE POLYNUCLEOTIDE ATTACHMENT | ILLUMINA, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
| US-8178490-B2 | Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100152098-A1 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | MPEX PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270883-A1 | ACTIVE AGENT RELEASE PARTICLE | AIFM2, ACR, SLC40A1 | CA1 1481/4885CA2 2111/4885CA12 2142/4885 |
| US-20240269094-A1 | Treatment of canine dermatitis and skin irritation | CUTA, TAS2R5, TAS2R13 | CA1 2912/4885CA2 1614/4885CA12 712/4885 |
| US-20100152098-A1 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | ABCB11, ABCB1, SLC47A1 | CA1 4829/4885CA2 3312/4885CA12 4636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.